poisar

Stocks · News reference

Moderna Q3 2026 Earnings Call Transcript

Earnings Transcripts

Moderna (NASDAQ:MRNA) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MRNA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Moderna (MRNA) Q3 Earnings and Revenues Top Estimates

    Moderna reported quarterly earnings of $0.38 per share, significantly beating the consensus estimate of a loss of $1.1 per share, with a 134.55% earnings surprise. The company posted revenues of $1.31 billion, surpassing estimates by 47.73%. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Moderna shares have gained 718.8% year-to-date, substantially outperforming the S&P 500's 7.4% gain.

    MRNASEPN
  3. Matt Frankel, Cfp®

    Moderna Just Gave Investors Yet Another Thing to Cheer About

    Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.

    MRNAMRK
  5. SEC EDGAR

    8-K filing — Moderna, Inc. (MRNA)

    Filed: 2026-11-06 AccNo: 0001682852-26-000194 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

    MRNA